<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04783207</url>
  </required_header>
  <id_info>
    <org_study_id>21.01.AMZ/ENDURO</org_study_id>
    <nct_id>NCT04783207</nct_id>
  </id_info>
  <brief_title>Effects of Mitopure (Urolithin A) on Skeletal Muscle Function, Iron Metabolism and Endurance Performance</brief_title>
  <acronym>ENDURO</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Mitopure (Urolithin A) on Skeletal Muscle Function, Iron Metabolism and Endurance Performance in Athletes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amazentis SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Australian Catholic University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Amazentis SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study enrolling 36 (16 Elite and 20&#xD;
      Sub-Elite trained endurance runners (18 placebo and 18 Mitopure intervention) who are 18-40&#xD;
      years of age. Mitopure or Placebo supplement, will be given as a daily oral dose for 4-weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma levels over time of creatine kinase (CK)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Muscle damage and recovery biomarker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in race performance time during a 3000 m track race in elite runners</measure>
    <time_frame>4-weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in aerobic capacity (VO2max)</measure>
    <time_frame>4-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in running economy via indirect calorimetry</measure>
    <time_frame>4-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lean body mass via Dual-energy X-ray Absorptiometry (DXA)</measure>
    <time_frame>4-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body fat mass via Dual-energy X-ray Absorptiometry (DXA)</measure>
    <time_frame>4-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Resting Metabolic Rate (RMR)</measure>
    <time_frame>4-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in maximal muscle strength during 1-repetition maximum leg press</measure>
    <time_frame>4-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in iron absorption and hemoglobin mass via determination of carboxyhaemoglobin (percent HbCO)</measure>
    <time_frame>4-weeks</time_frame>
    <description>only in sub-elite runners</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in acylcarnitines levels via metabolomics in plasma</measure>
    <time_frame>4-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in mitochondrial function via respirometry in muscle biopsies (sub-elite runners only)</measure>
    <time_frame>4-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in mitochondrial gene expression via RNA-seq in muscle biopsies (sub-elite runners only)</measure>
    <time_frame>4-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in plasma levels of Urolithin A</measure>
    <time_frame>4-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in plasma levels of inflammatory marker CRP</measure>
    <time_frame>4-weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Supplement containing Mitopure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Supplement</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mitopure</intervention_name>
    <description>Softgel containing 250 mg of Urolithin A (Mitopure) with excipients. 4 soft-gels to be taken daily</description>
    <arm_group_label>Supplement containing Mitopure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Softgel containing only excipients. 4 soft-gels to be taken daily</description>
    <arm_group_label>Placebo Supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18-40 years&#xD;
&#xD;
          -  Participants will be running &gt;100 km/week&#xD;
&#xD;
          -  Elite participants will be required to have a 3,000 m running personal best time below&#xD;
             9:00 (mm:ss), and/or a VO2max result greater than 65 ml路kg-1路min-1&#xD;
&#xD;
          -  The sub-elite cohort will have a 3,000 m running personal best faster than 10:00 min&#xD;
             and/or a VO2max &gt;60 ml路kg-1路min-1&#xD;
&#xD;
          -  Agree to participate in one of two ~4 week training camps been held between&#xD;
             March-October 2021.&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with diagnosed medical conditions involving thyroid function or other chronic&#xD;
             disturbances of metabolic rate&#xD;
&#xD;
          -  Subjects who are unable to complete the training or testing protocols&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Trained elite and sub-elite male runners will participate in a sports training camp</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louise Burke, OAM PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Australian Catholic University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anurag Singh, MD, PhD</last_name>
    <phone>+41215521274</phone>
    <email>asingh@amazentis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Australian Catholic University/Australian Institute of Sports</name>
      <address>
        <city>Canberra</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Burke, OAM PhD APD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

